{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:15:33Z","timestamp":1789643733655,"version":"4.0.0"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Prenatal Diagnosis"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>When treated for childhood cancers, at least 50% of children exposed to platinum agents have permanent hearing loss. We determined the relative risk of childhood hearing loss after in utero exposure to platinum chemotherapy in our registry cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>After exposure to platinum chemotherapy in utero, all children undergo routine newborn hearing screening. This consists of Otoacoustic Emissions. Children who failed this screen were evaluated by audiologists. For those children with hearing loss by Automated Auditory Brainstem Response, prenatal and postnatal treatment details were compared to platinum exposed children without hearing loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred and seven children were exposed to chemotherapy in utero. Four children were diagnosed with hearing loss, all exposed to platinum agents. Chemotherapy exposures included: Cisplatin\/Paclitaxel (2), Etoposide\/Cisplatin\/Bleomycin (1), Carboplatin\/Paclitaxel (1) to treat ovarian (2), or cervical cancer (2). Of the 39 platinum exposed without hearing loss: 11 children were exposed to oxaliplatin, 16 were exposed to cisplatin and 12 to carboplatin in utero. Two hundred and sixty four women received non\u2010platinum based chemotherapy for various cancers during pregnancy. Among these, there were no cases of hearing loss. There was a significant difference in hearing loss based on exposure to platinum agents in utero compared to non\u2010platinum\u2010containing chemotherapy regimens, 4\/43 versus 0\/264, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0003. There were no statistical differences in prenatal and postnatal treatment details, including: gestational age at diagnosis, at first chemotherapy treatment, at first platinum treatment, at delivery (&lt;32\u00a0weeks, &lt;35\u00a0weeks, &lt;37\u00a0weeks), gender, birthweight, birthweight percentile, rates of intrauterine growth restriction, neonatal complications or use of postnatal antibiotics between the platinum exposed children with and without hearing loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The only children in the registry exposed to chemotherapy who were diagnosed with hearing loss had been exposed to cisplatin or carboplatin in utero. No hearing loss occurred in children exposed to oxaliplatin, or non\u2010platinum agents. Due to a concern for cisplatin ototoxicity, carboplatin is the preferred platinum agent for use in pregnancy when equivalent maternal survival can be expected for the particular cancer type. For newborns exposed to platinum agents in utero, newborn screening with an auditory emissions test at birth (OES) may not detect sensorineural hearing loss and auditory brainstem response testing is recommended, regardless of the newborn screening result.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pd.6035","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T02:49:28Z","timestamp":1630378168000},"page":"1467-1474","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incidence of childhood hearing loss after in utero exposure to platinum agents"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-5313","authenticated-orcid":false,"given":"Lauren E.","family":"Finch","sequence":"first","affiliation":[{"name":"Cooper Medical School of Rowan University  Camden New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyce H.","family":"Cardonick","sequence":"additional","affiliation":[{"name":"Maternal Fetal Medicine Department Cooper University Hospital Cooper Medical School of Rowan University  Camden New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Potential Cause of Cisplatin\u2010Linked Hearing Loss Identified","author":"NCI Staff","year":"2018"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb00277.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0629-8"},{"key":"e_1_2_8_5_1","first-page":"83","article-title":"Ototoxicity\u2010related disequilibrium","volume":"59","author":"Lheureux P","year":"2004","journal-title":"J Pharm Belg"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1597"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.5355"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016489.2013.879740"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1989.tb03389.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000389"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70363-1"},{"key":"e_1_2_8_12_1","first-page":"57","article-title":"Data describing child development at 6 years after maternal cancer diagnosis and treatment during pregnancy","volume":"138","author":"Van Gerwen M","year":"2020","journal-title":"Data Brief"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.02.022"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz228"},{"key":"e_1_2_8_15_1","volume-title":"Customised Centile Calculator GROW v8.0.2","author":"Gardosi FA","year":"2018"},{"key":"e_1_2_8_16_1","first-page":"493","article-title":"Uses and abuses of hearing loss classification","volume":"23","author":"Clark JG","year":"1981","journal-title":"Asha"},{"key":"e_1_2_8_17_1","volume-title":"Hearing Loss: Determining Eligibility for Social Security Benefits","author":"Dobie RA","year":"2004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.09.006"},{"key":"e_1_2_8_19_1","first-page":"14","article-title":"Cisplatin and carboplatin\u2010induced ototoxicity in children: clinical aspects and perspectives for prevention","volume":"22","author":"Montaguti M","year":"2002","journal-title":"ACTA Otorhinolaryngologica Itallica"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-013-9489-3"},{"key":"e_1_2_8_21_1","first-page":"676","article-title":"Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer","volume":"14","author":"Oh SY","year":"2013","journal-title":"JOP"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/014556131008900607"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000023"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-010-0543-7"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn418"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10162-020-00759-y"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5955(96)00075-5"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2008.06.004"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2809"},{"key":"e_1_2_8_30_1","first-page":"338","article-title":"Sensorineural hearing loss after occlusion of the enlarged vestibular aqueduct","volume":"20","author":"Welling D","year":"1999","journal-title":"Am J Otolaryngol"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.024208"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000335119"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5876(98)00123-2"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.21.2625"},{"key":"e_1_2_8_35_1","unstructured":"National Institute on Deafness and Other Communication Disorders (NIDCD). Enlarged vestibular aqueducts and childhood hearing loss.www.nidcd.nih.gov\/health\/hearing\/eva.asp. Accessed December 9 2009."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000185596.20207.d2"},{"key":"e_1_2_8_37_1","unstructured":"Spacer issues\u00a0& evidence: prevalence of congenital hearing loss. Preparing to Teach Committing to Learn | EHDI Learning Center | NCHAM National Center for Hearing Assessment\u00a0& Management (NCHAM) 30 Sept. 2010.www.infanthearing.org\/summary\/prevalence.html"}],"container-title":["Prenatal Diagnosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pd.6035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pd.6035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pd.6035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:00:24Z","timestamp":1693314024000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/pd.6035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/pd.6035"],"URL":"https:\/\/doi.org\/10.1002\/pd.6035","archive":["Portico"],"relation":{},"ISSN":["0197-3851","1097-0223"],"issn-type":[{"value":"0197-3851","type":"print"},{"value":"1097-0223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]},"assertion":[{"value":"2021-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}